Full TitleCRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the safety and effectiveness of the investigational drug seribantumab in people with metastatic solid tumors that have a fusion between the NRG1 gene and another gene. Seribantumab blocks proteins made by the NRG1 gene fusion, preventing them from activating another protein that causes cells to multiply. This blocking action may stop cancer cells from growing and dividing. Seribantumab is given intravenously (by vein).
To be eligible for this study, patients must meet several requirements, including:
- Participants must have a metastatic solid tumor that has continued to grow despite prior treatment.
- Patients’ tumors must contain an NRG1 gene fusion.
- At least 4 weeks must pass between the completion of previous therapy and receipt of seribantumab.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Alison Schram at 646-888-5388.